Propanc Biopharma, Inc. (PPCB): Insider Trading, Congress Trades & Research | Tormere

PPCB

$1.71-0.58%visit website

Propanc Biopharma, Inc.

Market Cap

$4M

Live price × Finnhub shares (2026-09-22)

Sector

Health Care

Industry

Biotechnology

Beta (raw)

3678.87

60mo monthly vs SPY

P/E (TTM)

—

Price / TTM diluted EPS

P/S (TTM)

—

Mkt cap / TTM revenue

P/B

—

Mkt cap / shareholders' equity

EV/EBITDA (TTM)

—

EV / TTM EBITDA

Loading…

Financial Statements

USD thousands	Q1 FY2026 Sep 30, 2025	Q2 FY2026 Dec 31, 2025	Q3 FY2026 Mar 31, 2026	Q4 FY2026 Jun 30, 2026	TTM Jun 30, 2026
Research & development	60	20	170	376	625
Total operating expenses	4,674	3,655	6,400	3,457	18,186
Operating income	(4,674)	(3,655)	(6,400)	(3,457)	(18,186)
Interest expense	306	59	38	28	431
Pretax income	(4,838)	(3,091)	(6,360)	(4,573)	(18,863)
Net income	(4,838)	(3,091)	(6,360)	(4,573)	(18,863)
EPS (basic) ($)	(0.39)	(0.30)	(7.00)		(17.62)
EPS (diluted) ($)	(0.39)	(0.30)	(7.00)		(17.62)
Weighted avg. shares (basic)	12,332	13,360	897
Weighted avg. shares (diluted)	12,332	13,360	897

Source: SEC XBRL filings (10-K, 10-Q). Per-share data in dollars; shares in thousands. Latest: 10-K filed Sep 25, 2026, period ended Jun 30, 2026. flagged for review— withheld, failed a consistency check restated or split-adjustedhover a value for its source

Showing the last 5 quarters. 59 more quarters, back to Dec 2010, with Tormere Pro.

Signals

Insider Velocity

no recent activity

purchases / sales, 90d

Market & Alt Data

News

15

recent articles

No Form 4 transactions on record.

Recent News

Propanc Biopharma, Inc. (PPCB) Stock Price, News, Quote & History

Yahoo! Finance Canada · 2026-11-03

Propanc Biopharma, Inc. (PPCB) stock price, news, quote and history

Yahoo Finance Australia · 2026-11-02

Propanc Biopharma Reports Preclinical Data with PRP & PRP plus TGF-β Inhibitor on TGF-β Pathway in Pancreatic Cancer

Yahoo · 2026-11-02

In lab tests, Propanc's PRP cut pancreatic cancer-cell growth about 50%, even in drug-resistant cells.

Stock Titan · 2026-11-02

Propanc Biopharma (PPCB) Stock Forecast & Analyst Ratings

Moomoo · 2026-10-31

Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients

Yahoo · 2026-10-30

A planned study could involve up to 50 cancer patients. Propanc's treatment components stayed detectable in blood for an hour.

Stock Titan · 2026-10-30

Propanc Biopharma Received Notice of Delisting

TradingView · 2026-10-29

Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients

Yahoo · 2026-10-28

Propanc Biopharma Continues Clinical Development Program For Propanc Proenzyme; Targets February 2027 For Its First Clinical Site Initiation

Benzinga · 2026-10-28

Propanc Biopharma (NASDAQ:PPCB) Penny Stock Falls 6% Pre-Market After a Reverse Split

kalkine.ca · 2026-10-27

Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability

Yahoo · 2026-10-26

Propanc Biopharma Announces New Preclinical Data Supporting Potential Of PRP To Treat Chemotherapy Resistance In Pancreatic Cancer; PRP Monotherapy Reduced Cancer Cell Proliferation By ~50–54% And Suppressed Long-term Clonogenic Survival By Up To 59%

Benzinga · 2026-10-26

Propanc Biopharma Inc (PPCB) Stock Price, Quote, News & History

Benzinga · 2026-10-26

CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

Yahoo · 2026-10-22

Informational purposes only, not investment advice.